|
WO2021072092A1
|
|
Non-animal softgel capsule formulations, methods of preparation, and methods of use thereof
|
|
WO2021022166A1
|
|
Antibody specific for gpc3 and methods of use thereof
|
|
WO2021016305A1
|
|
Softshell capsule formulations, and methods of preparation and use thereof
|
|
WO2021011538A1
|
|
Capsule dosage forms, methods of preparation and methods of use thereof
|
|
WO2021011177A1
|
|
Enteric proton pump inhibitor softgel capsule
|
|
WO2020247352A1
|
|
Delayed release softgel capsules
|
|
WO2020219499A1
|
|
Mini softgel naproxen composition
|
|
US2020323985A1
|
|
Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
|
|
WO2020210185A1
|
|
Analytical method for determining the total amount of a coating polymer in a dosage form
|
|
WO2020154437A1
|
|
Glycoside-containing peptide linkers for antibody-drug conjugates
|
|
WO2020112953A1
|
|
Apparatus and process for secondary encapsulation of solid inclusions using the rotary die process
|
|
WO2020096775A1
|
|
Sulfatase-cleavable linkers for antibody-drug conjugates
|
|
WO2021066840A1
|
|
Anti-cd25 antibody-maytansine conjugates and methods of use thereof
|
|
CA3112038A1
|
|
Solid or semisolid lipid based dosage form stabilization through curing and addition of low hlb surfactant(s)
|
|
BR112020018277A2
|
|
ENTERIC MOLE GELATINE CAPSULES
|
|
US2021046013A1
|
|
Enteric softgel capules
|
|
CA3091678A1
|
|
Pharmaceutical dosage form for an emulsion of simethicone and loperamide
|
|
WO2018169953A1
|
|
Antibody conjugates and methods of making and using the same
|
|
CA3048199A1
|
|
Multiple-fill/chamber softgel die
|
|
MX2019005930A
|
|
Accelerated drying of soft capsules in a controlled environment.
|
